Replimune REPL
NASDAQ REPL
$15.02 -0.27 (-1.77%)
As of: Sep 4, 2026 · 12:51 PM EDT

Replimune (REPL) Income towards Parent Company (2017 - 2026)

Replimune (REPL) posted Income towards Parent Company of -$73.2 million for Q1 2026, down 3.14% sequentially from -$70.9 million in Q4 2025, and up 1.34% YoY from -$72.2 million in Q1 2025.

Analysis

Replimune (REPL) Income towards Parent Company (2017 - 2026) Analysis & Trends

Replimune has reported Income towards Parent Company for 10 years, with the latest figure at -$73.2 million in Q1 2026.

  • Quarterly Income towards Parent Company rose 1.34% year-over-year to -$73.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$395.8 million (down 60.01% YoY) and the FY2026 annual result came in at -$313.9 million, down 26.91% from the prior year.
  • Income towards Parent Company slipped to -$73.2 million in Q1 2026 per REPL's latest filing, from -$70.9 million in the prior quarter.
  • Over five years, Income towards Parent Company peaked at -$31.6 million in Q1 2022 and troughed at -$128.7 million in Q2 2025.
  • A 5-year average of -$62.6 million and a median of -$53.8 million in 2024 frame the typical range for Income towards Parent Company.
  • The sharpest annual moves came in 2022 and 2025: Income towards Parent Company surged 51.52% in 2022, then plunged 139.39% in 2025.
  • Over 5 years, Income towards Parent Company stood at -$39.7 million in 2022, then fell by 28.8% to -$51.1 million in 2023, then declined by 29.77% to -$66.3 million in 2024, then declined by 6.94% to -$70.9 million in 2025, then retreated by 3.14% to -$73.2 million in 2026.
  • According to Business Quant data, Income towards Parent Company over the past three periods registered -$73.2 million, -$70.9 million, and -$122.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 139.62 Bn 131.77 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.73 Bn 77.73 Bn 3.93 Bn
3 Argenx Se 63.53 Bn 58.35 Bn 1.37 Bn
4 Moderna 58.23 Bn 53.09 Bn 52.00 Mn
5 Revolution Medicines 44.05 Bn 44.05 Bn -
6 BeOne Medicines 40.03 Bn 34.93 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.50 Bn 32.19 Bn 992.69 Mn
8 Royalty Pharma 28.52 Bn 27.68 Bn -
9 Insmed 27.46 Bn 26.30 Bn 358.27 Mn
10 Replimune 1.46 Bn 1.46 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -68.87 Mn
Mar 31, 2026 -73.17 Mn
Dec 31, 2025 -70.93 Mn
Sep 30, 2025 -82.08 Mn
Jun 30, 2025 -87.18 Mn
Mar 31, 2025 -74.14 Mn
Dec 31, 2024 -66.37 Mn
Sep 30, 2024 -53.06 Mn
Jun 30, 2024 -53.77 Mn
Mar 31, 2024 -55.05 Mn
Dec 31, 2023 -51.15 Mn
Sep 30, 2023 -60.04 Mn
Jun 30, 2023 -49.56 Mn
Mar 31, 2023 -49.25 Mn
Dec 31, 2022 -39.69 Mn
Sep 30, 2022 -43.10 Mn
Jun 30, 2022 -42.25 Mn
Mar 31, 2022 -31.86 Mn
Dec 31, 2021 -29.61 Mn
Sep 30, 2021 -29.17 Mn